A detailed history of Ifp Advisors, Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ifp Advisors, Inc holds 4,369 shares of APLS stock, worth $145,094. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,369
Previous 3,698 18.14%
Holding current value
$145,094
Previous $217,000 23.04%
% of portfolio
0.01%
Previous 0.01%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$38.07 - $59.71 $25,544 - $40,065
671 Added 18.14%
4,369 $167,000
Q1 2024

Jul 30, 2024

SELL
$55.39 - $72.47 $1,717 - $2,246
-31 Reduced 0.83%
3,698 $217,000
Q4 2023

Jan 09, 2024

SELL
$37.14 - $64.82 $2,859 - $4,991
-77 Reduced 2.02%
3,729 $223,000
Q3 2023

Oct 12, 2023

BUY
$23.65 - $89.22 $44,036 - $166,127
1,862 Added 95.78%
3,806 $144,000
Q2 2023

Aug 04, 2023

SELL
$76.68 - $93.31 $3,143 - $3,825
-41 Reduced 2.07%
1,944 $177,000
Q1 2023

Apr 18, 2023

BUY
$46.59 - $66.96 $92,294 - $132,647
1,981 Added 49525.0%
1,985 $130,000
Q4 2022

Feb 07, 2023

BUY
$43.24 - $61.04 $172 - $244
4 New
4 $1,000
Q3 2021

Oct 06, 2021

SELL
$31.4 - $69.84 $31 - $69
-1 Closed
0 $0
Q2 2021

Jul 13, 2021

BUY
$40.9 - $64.9 $40 - $64
1 New
1 $0

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.65B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.